Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Health in 2026: a crash course

    In the US a new medicine needs an approved application before it can be sold, and clinical trials are the main way researchers find out whether a treatment is safe and effective.[1][2] Recent changes include the first FDA-cleared blood test used in diagnosing Alzheimer's disease in May 2025 and a new US cholesterol guideline in March 2026.[3][4]

    Editor reviewedStrict sourcingUpdated Explainer62 claims · 94% primaryHealth and medicine, Life sciences

    Health news is full of new drugs, new tests and new guidelines, and each rests on a chain of trials, reviews and recommendations. In the US, a new drug cannot be sold until the FDA has approved a marketing application, and the data behind that application come from clinical trials.[1][2] This crash course explains that chain first, then introduces the agencies involved, then points to ContentLora’s explainers on common conditions, trackers and debates.

    This page is general information, not medical advice. It does not tell you what to take or how much. Talk to a doctor, pharmacist or other qualified clinician about your own health, tests and treatment.

    How a medicine gets from the lab to the pharmacy

    Before testing an experimental drug in people, a sponsor files an Investigational New Drug (IND) application, because federal law otherwise bars shipping an unapproved drug across state lines.[5] The FDA has 30 days to review it and can place a clinical hold, though the agency says holds are rare.[6]

    Trials then run in phases. The FDA describes Phase 1 as 20 to 100 people testing safety and dosage, with about 70% of drugs moving on; Phase 2 as up to several hundred people, with about 33% moving on; and Phase 3 as 300 to 3,000 people over one to four years.[7][8][9] In a randomised trial, chance decides who gets which treatment, so the groups are similar; in a double-blind trial, neither patients nor researchers know who gets what until the end, which makes results less likely to be biased.[10][11]

    A drug company then submits a New Drug Application, or a Biologics License Application for biological products such as antibodies.[1][12] Several programmes can speed things up: Fast Track, Breakthrough Therapy designation, Priority Review and Accelerated Approval, which since 1992 has allowed approval based on a surrogate endpoint for serious conditions with unmet need.[13][14][15] The FDA says Priority Review shortens the timetable but does not lower the standard of evidence.[16] Dietary supplements follow a different path: the FDA cannot approve them before they are sold.[17] The step-by-step guides are how FDA drug approval works and how clinical trials work.

    Who sets the rules: FDA, CDC, WHO and the USPSTF

    The FDA is part of the US Department of Health and Human Services and oversees the safety and efficacy of drugs, biological products and medical devices, as well as the safety of the food supply.[18][19] It lost about 3,500 jobs in the 2025 HHS workforce cuts.[20] In May 2026 President Trump said Commissioner Marty Makary was leaving and that Kyle Diamantas would lead the agency in an acting capacity; an FDA release dated 14 October 2026 still described Diamantas as acting commissioner.[21][22] A recall is a firm’s action to remove a product from the market, voluntarily, at the FDA’s request or by FDA order. The most serious class, Class I, covers products with a reasonable probability of causing serious harm or death; see the fda-recall-process page.[23][24]

    The CDC collects case reports from state and local health departments through its notifiable diseases system, and sets vaccine schedules based on its advisory committee, ACIP.[25][26] As of 7 November 2026, CDC listed every 2026 ACIP meeting as cancelled because of litigation.[27]

    The WHO is the United Nations’ health agency.[28] According to HHS, the United States formally left WHO on 22 January 2026.[29]

    The uspstf grades preventive services such as screening tests, and its grades decide which services many Americans can get at no cost.[30][31] As of September 2026 it had not met for more than a year.[32]

    Heart, metabolism and diet

    Cholesterol is a waxy substance made by the liver, and a standard blood test measures LDL, HDL, triglycerides and total cholesterol.[33][34] A new US guideline published in March 2026 replaced the 2018 version, brought back LDL treatment goals and recommends measuring Lp(a) at least once in adulthood.[4][35][36] In July 2026 the FDA approved Lipfendra, the first oral PCSK9 inhibitor.[37] Start with cholesterol explained; the cholesterol and fasting tracker follows new results.

    Type 2 diabetes accounts for about 90% to 95% of the more than 40 million Americans with diabetes, according to the CDC.[38] In the Diabetes Prevention Program, a lifestyle programme cut new cases of type 2 diabetes by 58% compared with placebo over an average of 2.8 years.[39] See type 2 diabetes explained.

    A February 2026 Cochrane review of 22 randomised trials found intermittent fasting may make little to no difference to weight loss compared with regular dietary advice, with low-certainty evidence.[40] A 2017 sports-nutrition position stand called creatine the most effective supplement for high-intensity exercise capacity, while a 2024 meta-analysis of creatine and cognition rated the evidence as moderate certainty for memory and low certainty for other measures such as attention and processing speed.[41][42] The intermittent fasting and creatine explainers set out what the trials show.

    Brain and nerve diseases

    Alzheimer’s disease is a progressive brain disorder that slowly destroys memory and thinking, and the National Institute on Aging says more than 6 million Americans may have it.[43][44] In large trials, two antibody drugs slowed decline on a dementia scale compared with placebo: in Clarity AD, lecanemab patients declined 0.45 points less than placebo on a dementia scale over 18 months, and in TRAILBLAZER-ALZ 2 donanemab patients declined 0.7 points less over 76 weeks.[45][46] Both drugs carry a boxed warning for brain swelling and bleeding seen on scans, known as ARIA.[47] See Alzheimer’s disease explained.

    ALS destroys the motor neurons that control movement and breathing.[48] No treatment stops or reverses it, and NINDS describes the effect of the approved disease-modifying drugs as modest.[49][50] In September 2026 Otsuka and Ionis announced that a phase 3 trial of ulefnersen in FUS-ALS met its primary endpoint.[51] See ALS explained and the ALS research tracker.

    Cancer screening and product safety

    Screening looks for cancer or pre-cancer in people without symptoms, which WHO distinguishes from early diagnosis of people who already have symptoms.[52] The USPSTF recommends mammograms every two years for women aged 40 to 74 and colorectal screening for adults aged 45 to 75.[53][54] Multi-cancer blood tests are debated: the large NHS-Galleri trial missed its primary endpoint, yet an FDA advisory panel voted 7-2 in September 2026 that the Galleri test’s benefits outweigh its risks.[55][56] Read cancer screening explained, then the multi-cancer test debate and the cancer screening tracker.

    In February 2023 the FDA warned people to stop using two brands of artificial tears because of bacterial contamination that could cause blindness or death.[57] In August 2026 Sterling Pharmaceutical Services began a nationwide recall of eye-care products for lack of assurance of sterility, and the FDA’s Enforcement Report of recalls can be searched online.[58][59] See eye drop safety explained and the eye drop recalls tracker.

    Suggested order: read the two process guides first, then the three agency pages, then the condition explainers that interest you. Finish with the debate and tracker pages, which change as new results arrive. Mental health and infectious diseases have their own crash courses.

    Mental health is covered in the mental health crash course, and flu, measles, meningitis and antibiotic resistance in the infectious disease crash course. Both draw on the same agencies: the CDC tracks outbreaks through its notifiable diseases system, and the FDA reviews the vaccines and drugs used against them.[25][19]

    More in Health & medicine

    Questions readers ask

    How long does an FDA drug review take?

    Under the current user-fee agreement (PDUFA VII), the FDA aims to act on 90% of standard applications for new drugs within 10 months of the 60-day filing date, and on 90% of priority applications within 6 months. Priority review speeds the timetable but does not lower the evidence standard.[60][16]

    What are the phases of a clinical trial?

    The FDA describes Phase 1 as 20 to 100 people testing safety and dosage, Phase 2 as up to several hundred people studying efficacy and side effects, and Phase 3 as 300 to 3,000 people showing whether a product offers a treatment benefit.[7][8][9]

    Does the FDA approve dietary supplements such as creatine?

    No. Under the Dietary Supplement Health and Education Act, the FDA does not have the authority to approve dietary supplements before they are marketed.[17]

    Is there a blood test for Alzheimer's disease?

    The FDA cleared the first blood test used in diagnosing Alzheimer's, Fujirebio's Lumipulse test, in May 2025 for adults 55 and older with symptoms, and cleared Roche's Elecsys pTau181 test for use in primary care in October 2025.[3][61]

    Has the FDA approved a multi-cancer blood test?

    Not as of 14 November 2026. An FDA advisory panel voted in favour of the Galleri test in September 2026, but the panel's vote does not bind the FDA, and Galleri's own site said the test had not been cleared or approved.[56][62]

    Who decides which cancer screenings are recommended in the US?

    The US Preventive Services Task Force grades screening and other preventive services from A to D, or issues an I statement, based on the evidence. Its grades determine which preventive services many Americans can get at no cost.[30][31]

    Sources

    · 62 claims from 36 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Since 1938 every new drug has needed an approved New Drug Application (NDA) before it can be sold in the US, and the animal and human data gathered under the IND become part of the NDA. confirmedas of 2026-11-07

    2. [2]

      The US National Institute on Aging describes clinical trials, which test a medical, surgical or behavioural intervention in people, as the primary way researchers determine whether a new treatment or prevention method is safe and effective. confirmedas of 2026-11-07

    3. [3]

      On 16 May 2025 FDA cleared the first blood test used in diagnosing Alzheimer's, Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, for adults 55 and older with signs and symptoms of the disease. confirmedas of 2026-11-07

    4. [4]

      On 13 March 2026 the ACC, AHA and nine other organisations published a new US Guideline on the Management of Dyslipidemia in JACC, covering high blood cholesterol, hypertriglyceridemia and elevated Lp(a); it retires and replaces the 2018 cholesterol guideline. confirmedas of 2026-10-11

    5. [5]

      Federal law requires a drug to have an approved marketing application before it is shipped across state lines, so a sponsor that wants to send an experimental drug to clinical investigators files an Investigational New Drug (IND) application to obtain an exemption. confirmedas of 2026-11-07

    6. [6]

      FDA has 30 days to review an original IND; it can let trials begin or place a clinical hold to delay or stop them, though FDA says holds are rare and it more often sends comments to improve the trial. confirmedas of 2026-11-07

      • Step 3: Clinical Research · US Food and Drug Administration · Primary source · IND Review and Approval (retrieved 2026-11-07)
      • Step 3: Clinical Research · US Food and Drug Administration · Primary source · IND Review and Approval (retrieved 2026-11-07)
    7. [7]

      FDA describes Phase 1 studies as involving 20 to 100 healthy volunteers or people with the condition for several months, with the purpose of testing safety and dosage; about 70% of drugs move on to the next phase. confirmedas of 2026-11-07

    8. [8]

      FDA describes Phase 2 studies as involving up to several hundred people with the condition for several months to 2 years, to study efficacy and side effects; about 33% of drugs move on to the next phase. confirmedas of 2026-11-07

    9. [9]

      FDA describes Phase 3 studies, sometimes called pivotal studies, as involving 300 to 3,000 people with the condition over 1 to 4 years, designed to show whether a product offers a treatment benefit; about 25-30% of drugs move on to the next phase. confirmedas of 2026-11-07

    10. [10]

      In a randomised trial, participants are divided into groups by chance, which makes the groups similar so that the effects of the treatments can be compared more fairly. confirmedas of 2026-11-07

    11. [11]

      In a double-blind trial, neither the participants nor the researchers know who is receiving which treatment until the trial is over, which makes the results less likely to be biased. confirmedas of 2026-11-07

    12. [12]

      Biological products are licensed through a Biologics License Application (BLA), the formal request to introduce a biological product into interstate commerce; if the data and the manufacturing facility meet FDA's standards, the agency issues a US license. confirmedas of 2026-11-07

    13. [13]

      Fast Track is meant to speed the development and review of drugs for serious conditions that fill an unmet medical need; it offers more frequent meetings and written communication with FDA and rolling review, in which completed sections of an application can be submitted before the whole application is finished. confirmedas of 2026-11-07

      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    14. [14]

      Breakthrough Therapy designation is for drugs for serious conditions where preliminary clinical evidence suggests a substantial improvement over available therapy; it includes all Fast Track features plus intensive FDA guidance from as early as Phase 1, and FDA answers requests within 60 days. confirmedas of 2026-11-07

    15. [15]

      FDA created Accelerated Approval in 1992 so that drugs for serious conditions with an unmet medical need could be approved on the basis of a surrogate endpoint. confirmedas of 2026-11-07

    16. [16]

      Priority Review means FDA aims to act on an application within 6 months instead of 10 under standard review; it goes to drugs that would significantly improve the treatment, diagnosis or prevention of serious conditions, and it does not lower the standard of evidence for approval. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    17. [17]

      Under the Dietary Supplement Health and Education Act, FDA does not have the authority to approve dietary supplements before they are marketed. confirmedas of 2026-10-11

    18. [18]

      FDA is a federal regulatory agency within the US Department of Health and Human Services. confirmedas of 2026-11-07

      • FDA Organization · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    19. [19]

      FDA is responsible for protecting public health by ensuring the safety, efficacy and security of human and veterinary drugs, biological products and medical devices, and the safety of the food supply, cosmetics and radiation-emitting products. confirmedas of 2026-11-07

      • What We Do · US Food and Drug Administration · Primary source · FDA Mission (retrieved 2026-11-07)
    20. [20]

      The FDA lost about 3,500 jobs in the 2025 Department of Health and Human Services workforce cuts announced in March 2025. confirmedas of 2026-07-28

    21. [21]

      On 12 May 2026 President Trump said FDA Commissioner Marty Makary was leaving the agency and that Deputy Commissioner for Food Kyle Diamantas would lead it in an acting capacity. confirmedas of 2026-05-12

    22. [22]

      As of an FDA press release dated 14 October 2026, Kyle Diamantas was serving as acting FDA commissioner. confirmedas of 2026-10-14

    23. [23]

      FDA describes a recall as a firm's action to remove a product from the market, conducted on the firm's own initiative, at FDA's request, or by FDA order under statutory authority. confirmedas of 2026-10-11

    24. [24]

      A Class I recall is a situation where there is a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death. confirmedas of 2026-10-11

    25. [25]

      CDC's National Notifiable Diseases Surveillance System (NNDSS) receives and shares case data from state, local and territorial health departments to help monitor, control and prevent serious diseases. confirmedas of 2026-01-14

      • About NNDSS · Centers for Disease Control and Prevention · Primary source · 2026-01-14 · Read through WebFetch (cdc.gov blocks curl); page updated 14 January 2026 (retrieved 2026-11-07)
    26. [26]

      The Advisory Committee on Immunization Practices (ACIP) is a federal advisory committee of medical and public health experts that develops recommendations on vaccine use, and CDC sets the US adult and childhood immunisation schedules based on its recommendations. confirmedas of 2025-08-12

      • About ACIP · Centers for Disease Control and Prevention · Primary source · 2025-08-12 · Read through WebFetch (cdc.gov blocks curl) (retrieved 2026-11-07)
      • About ACIP · Centers for Disease Control and Prevention · Primary source · 2025-08-12 · Read through WebFetch (cdc.gov blocks curl) (retrieved 2026-11-07)
    27. [27]

      As of 7 November 2026, CDC listed ACIP's last meeting as 4-5 December 2025 and its March, June and October 2026 meetings as cancelled due to ongoing litigation, with meetings scheduled for 2027. confirmedas of 2026-11-07

      • ACIP Meetings · Centers for Disease Control and Prevention · Primary source · 2026-10-09 · Read through WebFetch (cdc.gov blocks curl) on 2026-11-07 about 15:15 UTC; page updated 9 October 2026 (retrieved 2026-11-07)
      • ACIP Meetings · Centers for Disease Control and Prevention · Primary source · 2026-10-09 · Re-checked by reviewer through WebFetch on 2026-11-07; 2025 list ends "December 4-5, 2025"; 2027 list starts "February 24-26" (retrieved 2026-11-07)
      • ACIP Meetings · Centers for Disease Control and Prevention · Primary source · 2026-10-09 · Re-checked by reviewer through WebFetch on 2026-11-07 (retrieved 2026-11-07)
    28. [28]

      WHO is the United Nations specialised agency for health; its Constitution was adopted on 22 July 1946 and entered into force on 7 April 1948. confirmedas of 2026-11-07

    29. [29]

      According to HHS, the United States formally exited WHO on 22 January 2026 after the one-year notice period, terminated all US government funding to WHO, and ceased official participation in WHO committees, governance bodies and technical working groups. confirmedas of 2026-02-23

    30. [30]

      The USPSTF gives each recommendation a letter grade (A, B, C, D or an I statement) based on the strength of evidence and the balance of benefits and harms, and does not consider cost. confirmedas of 2026-10-11

      • About the USPSTF · US Preventive Services Task Force · Primary source · What We Do (retrieved 2026-10-11)
      • About the USPSTF · US Preventive Services Task Force · Primary source · What We Do (retrieved 2026-10-11)
    31. [31]

      USPSTF recommendations determine which preventive services, such as screening colonoscopies and mammograms, many Americans can get at no cost. confirmedas of 2026-10-11

    32. [32]

      As of September 2026 the USPSTF had not met for more than a year after its meetings were cancelled by HHS Secretary Robert F. Kennedy Jr. confirmedas of 2026-09-17

    33. [33]

      The CDC describes blood cholesterol as a waxy, fat-like substance made by the liver, and says the body makes all the blood cholesterol it needs. confirmedas of 2026-10-11

      • About Cholesterol · Centers for Disease Control and Prevention · Primary source · What it is (retrieved 2026-10-11)
      • About Cholesterol · Centers for Disease Control and Prevention · Primary source · What it is (retrieved 2026-10-11)
    34. [34]

      A standard cholesterol check (lipid panel) measures LDL cholesterol, which can lead to plaque buildup in arteries; HDL cholesterol, high levels of which are linked to lower heart disease and stroke risk; triglycerides, a blood fat used for energy; and total cholesterol. confirmedas of 2026-10-11

      • About Cholesterol · Centers for Disease Control and Prevention · Primary source · What do blood cholesterol numbers mean? (retrieved 2026-10-11)
      • About Cholesterol · Centers for Disease Control and Prevention · Primary source · What do blood cholesterol numbers mean? (retrieved 2026-10-11)
    35. [35]

      The 2026 ACC/AHA guideline brings back LDL cholesterol treatment goals of below 100 mg/dL for people at borderline or intermediate risk, below 70 mg/dL at high risk, and below 55 mg/dL for secondary prevention in people with ASCVD at very high risk. confirmedas of 2026-10-11

    36. [36]

      The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood (a Class I recommendation), noting that lifestyle changes minimally affect Lp(a) so repeat testing is generally not needed. confirmedas of 2026-10-11

    37. [37]

      The FDA approved Merck's enlicitide (Lipfendra) 20 mg tablets in July 2026 (FDA action date 15 July; Merck announced it on 16 July) to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, making it the first FDA-approved oral PCSK9 inhibitor. confirmedas of 2026-10-11

    38. [38]

      The CDC says more than 40 million Americans have diabetes, about 1 in 8, and that about 90% to 95% of them have type 2 diabetes. confirmedas of 2026-11-07

      • Type 2 Diabetes · Centers for Disease Control and Prevention · Primary source · 2024-05-15 · Overview (cached by fetch-source 2026-11-07) (retrieved 2026-11-07)
    39. [39]

      Over an average 2.8 years of follow-up, the DPP lifestyle programme reduced the incidence of type 2 diabetes by 58% and metformin by 31% compared with placebo, and the lifestyle programme was significantly more effective than metformin. confirmedas of 2026-11-07

    40. [40]

      A February 2026 Cochrane review of 22 randomised trials (1,995 adults with overweight or obesity, follow-up up to 12 months) covering time-restricted feeding, periodic fasting and alternate-day fasting, found intermittent fasting may result in little to no difference in weight loss compared with regular dietary advice (low-certainty evidence). confirmedas of 2026-10-11

    41. [41]

      The International Society of Sports Nutrition's 2017 position stand concluded that creatine monohydrate is the most effective nutritional supplement available to athletes for increasing high-intensity exercise capacity and lean body mass during training. confirmedas of 2017-06-13

    42. [42]

      The 2024 meta-analysis rated the certainty of evidence as moderate for memory and low for processing speed, overall cognition, executive function and attention. confirmedas of 2024-07-12

    43. [43]

      Alzheimer's disease is a progressive brain disorder that slowly destroys memory and thinking skills and eventually the ability to carry out simple tasks; symptoms usually first appear later in life. confirmedas of 2026-11-07

    44. [44]

      The National Institute on Aging says estimates vary but more than 6 million Americans, most aged 65 or older, may have Alzheimer's; it is the seventh leading cause of death in the US and the most common cause of dementia in older adults. confirmedas of 2026-11-07

    45. [45]

      In Clarity AD the CDR-SB dementia score worsened by 1.21 points on lecanemab and 1.66 on placebo over 18 months, a difference of 0.45 points that the authors called moderately less decline, with adverse events. confirmedas of 2026-11-07

    46. [46]

      In TRAILBLAZER-ALZ 2 (1,736 participants), the CDR-SB score worsened by 1.72 points on donanemab and 2.42 on placebo over 76 weeks in the combined population, a difference of 0.7 points; treatment was switched to placebo once amyloid fell enough. confirmedas of 2026-11-07

    47. [47]

      ARIA usually appears as temporary brain swelling on scans that resolves over time, sometimes with small spots of bleeding; it often causes no symptoms, but serious and life-threatening events can occur, and both drugs carry a boxed warning for ARIA. confirmedas of 2026-11-07

    48. [48]

      Amyotrophic lateral sclerosis (ALS), formerly known as Lou Gehrig's disease, is a progressive neurological disorder affecting motor neurons, the nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing. confirmedas of 2026-10-11

    49. [49]

      There is no treatment that stops or reverses ALS; approved drugs may prolong survival, slow decline or manage symptoms. confirmedas of 2026-10-11

    50. [50]

      NINDS says the FDA has approved one symptom-managing and four disease-modifying ALS therapies, but the impact of the disease-modifying therapies is modest. confirmedas of 2026-10-11

    51. [51]

      On 22 September 2026 Otsuka and Ionis announced that the phase 3 FUSION trial of ulefnersen in FUS-ALS met its primary endpoint, a joint-rank measure of function and survival through day 505 (p=0.0005 versus placebo). confirmedas of 2026-09-22

    52. [52]

      WHO distinguishes early diagnosis of symptomatic cancer from screening, which aims to find cancer or pre-cancer in people before symptoms develop. confirmedas of 2026-10-11

      • Cancer (fact sheet) · World Health Organization · Primary source · Early detection (retrieved 2026-10-11)
      • Cancer (fact sheet) · World Health Organization · Primary source · Screening (retrieved 2026-10-11)
    53. [53]

      The USPSTF (April 2024) recommends biennial screening mammography for women aged 40 to 74 (grade B). confirmedas of 2026-10-11

    54. [54]

      The USPSTF (May 2021) recommends colorectal cancer screening for all adults aged 50 to 75 (grade A) and adults aged 45 to 49 (grade B), and selective screening at 76 to 85 (grade C). confirmedas of 2026-10-11

    55. [55]

      NHS-Galleri missed its primary endpoint; the rate of stage III or IV cancer across 12 prespecified cancer types did not differ significantly between groups after three rounds (incidence rate ratio 1.03, 95% CI 0.92 to 1.14). confirmedas of 2026-10-11

    56. [56]

      On 23 September 2026 an FDA advisory panel voted 7-2 with one abstention that Galleri's benefits outweigh its risks, unanimously on safety, and 6-4 on effectiveness, for screening adults aged 50 and older; the FDA is not bound by the vote. confirmedas of 2026-09-23

    57. [57]

      On 2 February 2023 FDA warned consumers and health care practitioners to stop using EzriCare Artificial Tears and Delsam Pharma's Artificial Tears because of potential bacterial contamination, saying contaminated artificial tears raise the risk of eye infections that could cause blindness or death. confirmedas of 2026-10-11

    58. [58]

      Sterling Pharmaceutical Services of Dupo, Illinois, began a nationwide recall of eye-care products on 20 August 2026 for lack of assurance of sterility; FDA classified it Class II on 21 September and posted it on 30 September 2026. confirmedas of 2026-10-11

    59. [59]

      Enforcement Report data can be accessed through a weekly report, quick and advanced search, and an application programming interface (API). confirmedas of 2026-10-11

      • Enforcement Reports · US Food and Drug Administration · Primary source (retrieved 2026-10-11)
    60. [60]

      Under PDUFA VII, FDA commits to review and act on 90% of standard new molecular entity NDAs and original BLAs within 10 months of the 60-day filing date, and 90% of priority ones within 6 months of that date. confirmedas of 2026-11-07

    61. [61]

      On 8 October 2025 FDA cleared Roche's Elecsys pTau181 blood test to aid the initial assessment of people aged 55 and older with cognitive decline; trade press, reporting Roche's announcement, described it as the first blood-based Alzheimer's biomarker test for use in primary care. confirmedas of 2026-11-14

    62. [62]

      As of November 14, 2026, the Galleri test had not been cleared or approved by the FDA; GRAIL's patient site still carried that statement, along with the note that GRAIL's laboratory is regulated under CLIA, and its November 4 results described the FDA decision as still to come. confirmedas of 2026-11-14

    Revision history (2)
    1. Re-checked the multi-cancer blood test FAQ: Galleri still not FDA-approved as of 14 November 2026.
    2. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.

    Cite this page

    "Health in 2026: a crash course." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/health

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.